April 8, 2021
2 mins read

‘Moderna more troublesome than Pfizer’

The study, published in the journal JAMA, analysed reports collected via a Centers for Disease Control and Prevention (CDC) programme called v-safe that tracks side effects in vaccine recipients….reports Asian Lite News

In a first, a new study has pointed out that those taking the Moderna vaccine have reported more side effects than people who get the Pfizer/BioNTech jabs.

The study, published in the journal JAMA, analysed reports collected via a Centers for Disease Control and Prevention (CDC) programme called v-safe that tracks side effects in vaccine recipients.

A total of 3,643,918 people were enrolled in v-safe and completed at least one health survey within seven days following their first vaccine dose before February 21, and 1,920,872 v-safe participants reported receiving a second vaccine dose and completed at least one daily health survey within seven days following the second dose.

Nearly 70 per cent of those said they had some kind of injection site reaction, like pain or swelling, and half had generalised reaction like fatigue or chills.

“A greater percentage of participants who received the Moderna vaccine, compared with the Pfizer-BioNTech vaccine, reported reactogenicity; this pattern was more pronounced after the second dose,” the researchers noted.

Also read:CDC reveals Pfizer, Moderna jabs effective in real world

Reactogenicity refers to a subset of reactions that occur soon after vaccination.

People who got a Moderna shot were more likely to have a side effect — 73 per cent had an injection site reaction, compared with 65 per cent of people who had a Pfizer/BioNTech dose.

Nearly 51 per cent of Moderna recipients had full-body symptoms, compared with 48 per cent of people who got the Pfizer/BioNTech shot.

The gap widened after the second dose.

Almost 82 per cent of people getting their second Moderna shot had injection site pain versus just under 69 per cent of people with Pfizer/BioNTech, reports The Verge.

“Overall, 74 per cent of people said they had general reactions after their Moderna shot, compared with 64 per cent of people getting Pfizer/BioNTech,” the report said on Tuesday.

Zulema Riquelme, a 46-year-old nursing technician, receives a shot of the COVID-19 vaccine at the Metropolitan Hospital in Santiago, Chile

People over 65 were also less likely to have side effects than people under 65, regardless of which vaccine they received.

“Data from millions of v-safe participants indicate that injection site pain is common after both the first and second doses of either mRNA-based vaccine,” the study noted.

Systemic reactions, including fatigue, headache, myalgia, chills, fever, and joint pain, occurred in participants after the first dose, although they were more frequently reported after the second dose among both Pfizer-BioNTech and Moderna vaccine recipients.

Also read:CDC reveals Pfizer, Moderna jabs effective in real world

Previous Story

Actor Amit Sadh leaves social media

Next Story

UK on track to inoculate all adult by July

Latest from -Top News

Opalz by Danube Opens with Eid Joy

Danube Properties celebrated the early completion of its Opalz project in Dubai Science Park with a vibrant Eid Festival, bringing the community together for three days of festivities. Danube Properties, one of

China to raise tariffs on US goods to 125%

Trump’s universal tariffs on China total 145%. When Trump announced Wednesday that China faced 125% tariffs, he did not include a 20% tariff on China tied to its role in fentanyl production

Thousands of immigrants off from Social Security

The policy aligns with other high-profile anti-immigration measures taken by Donald Trump’s White House since his second term began, including sending more than 200 suspected gang members to a notorious prison in
Go toTop

Don't Miss

‘India to touch 100 cr Covid vaccination mark next week’

The minister made the remark after launching India’s Covid-19 vaccination

Israel research: Covid-19 virus harms human immune system

Israeli researchers have found that SARS-CoV-2, the virus that causes